{"ok":true,"entity":{"id":"intellia-therapeutics","name":"Intellia Therapeutics","entityType":"company","officialName":"Intellia Therapeutics, Inc.","canonicalName":"Intellia Therapeutics","displayName":"Intellia Therapeutics","category":"in vivo遺伝子編集","shortDescription":"体外で細胞を編集して戻すのではなく、体内へ直接編集試薬を投与するin vivo方式のCRISPR-Cas9治療を開発する米国企業。遺伝性血管性浮腫（HAE）を対象とするlonvoguran ziclumeran（lonvo-z）で第3相を完了し、FDAへのローリングBLA提出を進めている。","primaryCluster":"biotech-genomics","parentEntity":null,"verificationStatus":"draft","website":"https://www.intelliatx.com","updatedAt":"2026-08-06T01:18:46.240Z","secondaryClusters":[],"alias":[],"searchKeywords":["in vivo遺伝子編集","CRISPR-Cas9"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-06-001","P-01-002"]}